Glympse’s technologies enable real-time measurement of protein activity to monitor disease status — all with a noninvasive blood test.
Creating next-generation diagnostics
Glympse’s disease-agnostic platform measures protein activity, which is downstream and distinct from DNA, RNA, or other protein-based diagnostics. Its lead indication is NASH (Non-Alcoholic Steatohepatitis), with more on the way.
Join our mission to revolutionize diagnostics
Glympse is transforming patient care with an innovative liquid biopsy that measures protein activity to diagnose and monitor disease. If that sounds like your kind of challenge, join us.